ImmunityBio, Inc. Common Stock

Pomerantz Law Firm has filed class action lawsuits against ImmunityBio, Inc., New Era Energy & Digital, Inc., and Vital Farms, Inc. for alleged securities fraud and unlawful business practices. The primary case involves ImmunityBio, which faced an FDA warning letter on March 24, 2026, for continuing to promote its bladder-cancer drug Anktiva in a...

Rosen Law Firm reminds ImmunityBio investors of the May 26, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that defendants made false and misleading statements about Anktiva's capabilities and ImmunityBio's business operations. Investors who purchased securities between January 19, 2026 and March 24, 2026 m...

The Schall Law Firm is seeking investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its Anktiva drug capabilities, causing investor losses when the truth was revealed.

Rosen Law Firm announces securities class action lawsuits against ImmunityBio, Inc. and other companies for allegedly making false and misleading statements. The firm is seeking lead plaintiffs with losses exceeding $100,000 before the May 26, 2026 deadline. According to the lawsuit, ImmunityBio's defendant Patrick Soon-Shiong materially overstat...

ImmunityBio (IBRX) is facing a securities class action lawsuit after the FDA issued a warning letter regarding misleading efficacy claims made by executive chairman Dr. Patrick Soon-Shiong about the company's drug Anktiva. The FDA determined that promotional materials falsely suggested Anktiva could treat all cancers, when it is only approved for...